ÖØÖ¢¼¡ÎÞÁ¦ÃâÒßÖÎÁÆÑо¿½øÕ¹

¡¡¡¡[6] Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis[J]. Cochrane Database Syst Rev£¬2007£¬17 (4): CD005224.

¡¡¡¡[7] Millind J, Kothari DO. Myasthenia gravis[J].JAOA, 2004, 104 (9): 377.

¡¡¡¡[8] Confavreax C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a caseª²control study[J]. Neurology, 1996, 46: 1607.

¡¡¡¡[9] Lavrnic D, Vujic A, Rakocevicª²Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis[J]. Acta Neurol Scand, 2005,111(4): 247.

¡¡¡¡[10] Wu JM, WU B, Miagkov A, et al. Specific immumotherapy of EAMG in vitro: the¡°guided missile¡± strategy[J]. Cell Immunol, 2001, 208(2): 137.

¡¡¡¡[11] ÀîÐ㻪,³ÌìÍ, ÑîÀö£¬µÈ.ÃâÒßÒÖÖƼÁ¶ÔÖØÖ¢¼¡ÎÞÁ¦²¡ÈËTÁÜ°Íϸ°ûÑÇÐ͵ÄÓ°Ïì[J].ÖйúʵÓÃÉñ¾­¼²²¡ÔÓÖ¾,2008,11(5):1ª²4.

¡¡¡¡[12] Im SH, Barchan D, Fuchs S, et al. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment[J]. J Clin Invest, 1999, 104(12): 172.

¡¡¡¡[13] Yang JS, Xu LY, Huang YM, et al. Adherent dendritic cells expressing high levels of interleukinª²10 and low levels of interleukinª²12 induce antigenª²specific tolerance to experimental autoimmune encephalomyelitis[J]. Immunology, 2002, 101 (3): 397.

¡¡¡¡[14] Ichikawa M, Koh CS, Hata Y, et al. Immunoadsorption plasmapheresis for severe generalized myasthenia gravis[J]. Arch Dis Child, 1993, 69: 236.

¡¡¡¡[15] Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorption of plasma[J]. Neurology, 1995, 45(2): 338.

¡¡¡¡[16] Ptak J, Lochman J. Immunoadsorption therapy and complement activation[J]. Transfus Apher Sci, 2005, 32(3): 263ª²267.

¡¡¡¡[17] Goto H, Matsuo H, Nadane, et al. Plasmapheresis affects T helper typeª²1/T helper typeª²2 balance of circulating peripheral lymphocytes [J]. Ther Apher, 2001, 5(6

ÉÏÒ»Ò³  [1] [2] [3] [4] ÏÂÒ»Ò³